Hypertension, commonly known as high blood pressure, remains one of the leading causes of heart disease and stroke in India. Despite advancements in medical science, many patients continue to struggle with uncontrolled hypertension even after taking multiple medications. However, a new breakthrough is set to transform the future of treatment.

We are proud to announce the enrollment of the first patient in the India arm of the GSR DEFINE Study, marking a significant milestone in advancing cardiovascular care. This study introduces an innovative approach known as Renal Denervation (RDN) therapy, offering hope to patients who have not achieved optimal blood pressure control through conventional methods.

Renal Denervation is a minimally invasive, device-based procedure that targets the nerves surrounding the kidneys. By modifying these overactive nerves, RDN helps regulate blood pressure more effectively. Unlike traditional treatments that rely solely on medication, this advanced therapy focuses on the underlying physiological causes of hypertension, providing a more sustainable and long-term solution.

This development represents a major step forward in hypertension treatment in India, especially for patients with resistant hypertension. With cutting-edge technology and ongoing clinical research, therapies like RDN are paving the way for improved patient outcomes and a better quality of life.

At the forefront of this innovation is Dr. Sarita Rao, a leading cardiologist in India, dedicated to bringing the latest advancements in heart care to patients. As research continues, such breakthroughs highlight the importance of combining expertise with modern technology to redefine cardiovascular treatment.

If you or your loved ones are struggling with uncontrolled blood pressure, exploring advanced treatment options like Renal Denervation could be life-changing.

Read Blog: High Blood Pressure (Hypertension)
For Previous Blog: Why Does Blood Pressure Fluctuate During Summer?